
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.
“We continue to see a building story of benefit of statin medications in men who have prostate cancer,” says Robert J. Hamilton, MD, MPH.
In this interview, Robert J. Hamilton, MD, MPH, discusses findings from a recent study published in European Urology titled, “The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy,” for which he served as a study author. Hamilton is an associate professor of urology at the University of Toronto.






